ICAR: endoscopic skull‐base surgery

n/

Transplantation in pediatric aHUS within the era of eculizumab therapy

aHUS is caused by the over-activation and dysregulation of the alternative complement pathway. Data regarding outcomes of pediatric aHUS patients after kidney transplantation are still very scarce. Accordingly, the aim of this study was to describe the clinical findings and outcomes of pediatric aHUS patients after renal transplantation. This is a retrospective, multicenter study including 12 patients from the national registry system. Among the 12 patients, eight had received prophylactic eculizumab and none of those patients (except one) had experienced aHUS recurrence during a median follow-up period of 58.5 (min-max, 4-94) months. Although eculizumab had been started on the day before transplantation in one of them, aHUS recurrence occurred during the transplantation procedure. Eculizumab had been stopped in only one patient who had no complement gene mutation after 35 months of therapy, and recurrence had not been observed during the 19 months of follow-up. In three patients, maintenance doses had been spaced out without any recurrence. One additional patient with anti-CFH antibody received only two doses of eculizumab for transplantation and had been followed for 46 months without aHUS recurrence. The remaining three patients had not received anti-C5 therapy and none of those patients experienced aHUS recurrence during a median follow-up period of 21 (min-max, 9-42) months. Prophylactic eculizumab is a safe and effective treatment for the prevention of aHUS recurrence. Eculizumab interval prolongation, discontinuation, and transplantation without eculizumab prophylaxis can be tried in selected patients with close follow-up.C1 [Ozcakar, Zeynep Birsin] Ankara Univ, Div Pediat Nephrol, Dept Pediat, Sch Med, Ankara, Turkey.[Ozaltin, Fatih; Gulhan, Bora; Topaloglu, Rezan] Hacettepe Univ, Div Pediat Nephrol, Dept Pediat, Fac Med, Ankara, Turkey.[Ozaltin, Fatih] Hacettepe Univ, Nephrogenet Lab, Fac Med, Ankara, Turkey.[Comak, Elif] Akdeniz Univ, Div Pediat Nephrol, Dept Pediat, Fac Med, Antalya, Turkey.[Parmaksiz, Gonul] Baskent Univ, Adana Teaching & Res Hosp, Pediat Nephrol, Adana, Turkey.[Baskin, Esra] Baskent Univ, Div Pediat Nephrol, Dept Pediat, Sch Med, Ankara, Turkey.[Kasap Demir, Belde] Izmir Katip Celebi Univ, Div Nephrol & Rheumatol, Dept Pediat, Fac Med, Izmir, Turkey.[Canpolat, Nur] Istanbul Univ, Div Pediat Nephrol, Dept Pediat, Cerrahpasa Fac Med, Istanbul, Turkey.[Yuruk Yildirim, Zeynep] Istanbul Univ, Div Pediat Nephrol, Dept Pediat, Istanbul Fac Med, Istanbul, Turkey.[Demircioglu Kilic, Beltinge] Gaziantep Univ, Div Pediat Nephrol, Dept Pediat, Fac Med, Gaziantep, Turkey.[Yuksel, Selcuk] Pamukkale Univ, Div Pediat Nephrol, Dept Pediat, Sch Med, Denizli, Turkey.[Soylemezoglu, Oguz] Gazi Univ, Div Pediat Nephrol, Dept Pediat, Sch Med, Ankara, Turkey

Defect-Mediated Lithium Adsorption and Diffusion on Monolayer Molybdenum Disulfide

Monolayer Molybdenum Disulfide (MoS2) is a promising anode material for lithium ion batteries because of its high capacities. In this work, first principle calculations based on spin density functional theory were performed to investigate adsorption and diffusion of lithium on monolayer MoS2 with defects, such as single- and few-atom vacancies, antisite, and grain boundary. The values of adsorption energies on the monolayer MoS2 with the defects were increased compared to those on the pristine MoS2. The presence of defects causes that the Li is strongly bound to the monolayer MoS2 with adsorption energies in the range between 2.81 and 3.80 eV. The donation of Li 2s electron to the defects causes an enhancement of adsorption of Li on the monolayer MoS2. At the same time, the presence of defects does not apparently affect the diffusion of Li, and the energy barriers are in the range of 0.25–0.42 eV. The presence of the defects can enhance the energy storage capacity, suggesting that the monolayer MoS2 with defects is a suitable anode material for the Li-ion batteries